Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7L0D

SARS-CoV-2 Main Protease (Mpro) in Complex with ML188

7L0D の概要
エントリーDOI10.2210/pdb7l0d/pdb
分子名称3C-like proteinase, N-[(1R)-2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-N-(4-tert-butylphenyl)furan-2-carboxamide (3 entities in total)
機能のキーワードsars-cov-2, covid19 protease, protease inhibitor, complex, hydrolase inhibitor complex, hydrolase, hydrolase-hydrolase inhibitor complex, hydrolase-inhibitor complex, hydrolase/inhibitor
由来する生物種Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2, COVID-19 virus)
タンパク質・核酸の鎖数1
化学式量合計34259.09
構造登録者
Lockbaum, G.J.,Lee, J.M.,Reyes, A.C.,Nalivaika, E.A.,Ali, A.,Yilmaz, N.K.,Thompson, P.R.,Schiffer, C.A. (登録日: 2020-12-11, 公開日: 2021-02-10, 最終更新日: 2023-10-18)
主引用文献Lockbaum, G.J.,Reyes, A.C.,Lee, J.M.,Tilvawala, R.,Nalivaika, E.A.,Ali, A.,Kurt Yilmaz, N.,Thompson, P.R.,Schiffer, C.A.
Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.
Viruses, 13:-, 2021
Cited by
PubMed Abstract: Viral proteases are critical enzymes for the maturation of many human pathogenic viruses and thus are key targets for direct acting antivirals (DAAs). The current viral pandemic caused by SARS-CoV-2 is in dire need of DAAs. The Main protease (M) is the focus of extensive structure-based drug design efforts which are mostly covalent inhibitors targeting the catalytic cysteine. ML188 is a non-covalent inhibitor designed to target SARS-CoV-1 M, and provides an initial scaffold for the creation of effective pan-coronavirus inhibitors. In the current study, we found that ML188 inhibits SARS-CoV-2 M at 2.5 µM, which is more potent than against SAR-CoV-1 M. We determined the crystal structure of ML188 in complex with SARS-CoV-2 M to 2.39 Å resolution. Sharing 96% sequence identity, structural comparison of the two complexes only shows subtle differences. Non-covalent protease inhibitors complement the design of covalent inhibitors against SARS-CoV-2 main protease and are critical initial steps in the design of DAAs to treat CoVID 19.
PubMed: 33503819
DOI: 10.3390/v13020174
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.39 Å)
構造検証レポート
Validation report summary of 7l0d
検証レポート(詳細版)ダウンロードをダウンロード

248942

件を2026-02-11に公開中

PDB statisticsPDBj update infoContact PDBjnumon